Johnson & Johnson (NYSE:JNJ) EVP Timothy Schmid Sells 1,322 Shares

Johnson & Johnson (NYSE:JNJ) EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,251,310.02. This trade represents a 4.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Timothy Schmid also recently made the following trade(s):

• On Wednesday, February 18th, Timothy Schmid sold 22,623 shares of Johnson & Johnson stock. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59.

Johnson & Johnson Trading Up 1.3%

Shares of JNJ stock traded up $3.04 during trading hours on Monday, reaching $245.53. The company’s stock had a trading volume of 9,620,834 shares, compared to its average volume of 9,545,482. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a one year low of $141.50 and a one year high of $246.96. The stock has a market capitalization of $591.70 billion, a P/E ratio of 22.22, a P/E/G ratio of 2.35 and a beta of 0.35. The firm’s fifty day simple moving average is $221.06 and its 200 day simple moving average is $199.44.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion during the quarter. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is presently 47.06%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Bullish analyst/retail coverage highlights JNJ as a long-term buy thanks to its dividend-king status, diversification and defensive growth profile. The Only Healthcare Stock I’d Buy and Never Sell Might Be Johnson & Johnson
• Positive Sentiment: Bloomberg/InsiderMonkey report that J&J is exploring a possible sale of its orthopedics unit DePuy Synthes as part of a separation plan — a divestiture could raise cash, simplify the company and boost stakeholder returns. Bloomberg Reports Potential Major Asset Sale by Johnson & Johnson (JNJ)
• Positive Sentiment: Forbes highlights a “triple threat” — oncology sales growth, MedTech rebound, and an earnings beat — supporting upside expectations and valuation momentum. Does JNJ Stock Still Offer Value?
• Positive Sentiment: J&J is in the S&P 500 spotlight with coverage noting recent strength and investor interest, which can attract flows and lift the share price. Johnson and Johnson Surges in s&p 500 Spotlight
• Neutral Sentiment: JNJ announced a first co-funding agreement with Blackstone — a strategic partnership that could finance growth initiatives but hasn’t materially moved the stock on its own. Johnson & Johnson (JNJ) Stock Flat despite First Co-funding Agreement with Blackstone
• Neutral Sentiment: Comparative sector analysis (vs. AbbVie) and commentary on JNJ’s $32B R&D push underline longer-term growth potential but are informational rather than immediate catalysts. Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
• Neutral Sentiment: Unusual options activity was reported — suggests elevated trader interest/speculation but not a direct directional signal. Johnson & Johnson Target of Unusually High Options Trading (NYSE:JNJ)
• Negative Sentiment: German drugmaker Bayer filed a lawsuit in New York against J&J and Janssen over its Nubeqa prostate cancer drug — legal risk and potential costs introduce downside risk and headline volatility. Bayer files lawsuit against Johnson & Johnson, Janssen Biotech
• Negative Sentiment: Commentary from Bayer frames J&J’s claims as false in ongoing disputes — continued litigation headlines could weigh on sentiment while outcomes remain uncertain. “J&J’s Claims of Superiority… Are False”: Johnson & Johnson Stock Rises despite Bayer Lawsuit

Hedge Funds Weigh In On Johnson & Johnson

Several large investors have recently bought and sold shares of the stock. Brighton Jones LLC increased its position in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the period. United Bank boosted its stake in Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after buying an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after buying an additional 692 shares during the period. Wealth Group Ltd. raised its stake in shares of Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock valued at $226,000 after buying an additional 168 shares in the last quarter. Finally, Matrix Asset Advisors Inc. NY lifted its holdings in shares of Johnson & Johnson by 6.5% during the 2nd quarter. Matrix Asset Advisors Inc. NY now owns 3,595 shares of the company’s stock worth $549,000 after acquiring an additional 220 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on JNJ. TD Cowen upped their price target on Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Freedom Capital downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 16th. Rothschild & Co Redburn lifted their price target on shares of Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research report on Thursday. Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. Finally, Leerink Partners boosted their price target on Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $232.70.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.